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Summary. The cell population kinetics of 3 transplantable tumours has been
studied under circumstances in which the tumour growth rate was modified by a
disturbance of the immunological status of the host. In 2 cases a complete arrest
of growth was achieved but in spite of this there was a barely significant change
in the median intermitotic time of proliferating cells. The data indicate that growth
retardation was associated with a reduction in the proportion of actively proliferating
cells and the rate of cell production, with or without an increase in the absolute
rate of cell loss.
LITTLE is known at the present time
about the extent to which immunological
factors affect the growth rate of estab-
lished tumours, and in cases where this
has been shown to occur the cellular
mechanisms are poorly understood. In
man there are well-documented cases of
spontaneous regression of tumours that
cannot be ascribed to hormonal dis-
turbance, and in certain classes of human
tumours there are clear indications of
immunological processes at work (Burkitt
and Kyalwazi, 1967; Bloom, Richardson
and Field, 1970). In some animal
tumours it has been possible to obtain
passive immunity to pre-existing tumour
by the administration of sensitized
heterologous lymphocytes and thereby
to produce temporary or even permanent
tumour regression (Alexander et al., 1968;
Delorme and Alexander, 1964). Attempts
are now being made to strengthen the
immune reaction against tumours by
a variety of means, notably by the
administration of BCG and killed tumour
cells (Mathe, Pouillart and Lapeyraque,
1969; Baldwin and Pimm, 1971). In
tissue culture, sensitized lymphocytes
have been shown to destroy L5178Y
mouse lymphoma cells provided that
their proportion is sufficiently high (Den-
ham et al., 1970). The in vitro growth of
these cells has also been shown to be
inhibited by serum antibodies (Young
and Vas, 1970).
The object of the present work was
to study how an immunological reaction
against tumour cells affects their pro-
liferation. The growth of a tumour is
the resultant of 3 main factors: the
proportion of cells that are proliferating
("growth fraction"), their average inter-
mitotic time (" cycle time ") and the
rate of cell loss (Steel, 1968). When
there is a slowing of tumour growth rate,
any or all of these parameters may
change. When regression occurs, the
rate of cell loss must exceed the rate of
cell production, and in tumours that are
normally losing cells this situation may
be achieved either by an increase in the
absolute rate of cell loss or by a decrease
in the rate of cell production.
A previous publication described the
cell population kinetics of Ehrlich ascites
tumour when transplanted into rats
(Janik, 1971). In this heterologous trans-
plantation situation, the tumour grew for
5-7 days and then was rejected; it was
found that the rejection was associated
with little change in cycle of those cells
that continued to proliferate and with
only slight lowering ofthe growth fraction.
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in the rate of cell loss. For the present
work we have tried to find transplanted
tumours which, although still growing in
the original strain of animal, nevertheless
can be made to change their growth rate
as a result ofa disturbance ofthe immuno-
logical status of the host.
L5178Y Mouse Lymiphoma
L5] 78Y lymphoma cells were main-
tained in tissue culture (Courtenay, 1969)
and transplanted subcutaneously in male
DBA/2 mice by the injection of between
1 and 3 x 106 tumour cells. This tumour
is known to be strongly antigenic. Pre-
immunization with 2 x 106 heavily irra-
diated cells 14 days beforehand prevented
the growth of 106 live cells in all reci-
pients. Spontaneous regressions were also
sometimes observed. In the present
experiments regression was induced or
accelerated by two intraperitoneal injec-
tions of 106 cells that had been irradiated
with 5000 rad of x-rays; these were
given on the 6th and 11th days after
implantation. The mean tumour volume
in treated animals reached a maximum
at about 14 days after implantation and
then began to decline (Fig. 1). H3-thy-
midine was given on day 15.
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BICR/A3 Osteosarcoma
This tumour arose in the upper third
of the tibia of a female August rat 38
weeks after it had received 400 rad whole
body x-irradiation. Radiographic exami-
nation showed the typical appearance of
an osteosarcoma and this was confirmed
histologically. The tumour was trans-
planted by means of a trocar within the
same strain and sex of animal and it
grew rapidly and reproducibly. In the
first transplant the volume doubling time
was about 2-5 days and at the time of
the present studies it was in its 25-30th
passage. Three groups of rats were used
in the present experiments. The first
were from a group of 30 that had been
injected subcutaneously with a cell suspen-
sion containing 106 trypan blue-excluding
cells. In 17 rats no tumour had appeared
at 40 days after implantation and these
were regarded as immunized. In the
second group of unimmunized rats the
immune response was depressed by giving
300 rad whole body x-irradiation 1 day
before trocar implant of the tumour.
The third group were untreated controls.
Measurement of tumour volume (Fig. 1),
showed that as expected the tumours
in the irradiated group were larger than
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FIG. 1.- Growth cuirves for control and treated animals in the 3 tuimour systems.
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in controls while those in the immunized
group were smaller. However, at the
time of thymidine administration (13-16
days after implantation) the differences in
tumour growth rate were not very large.
BICR/A12 Adenocarcinoma
This was a mammary adenocarcinoma
that had been induced in an August
female rat by an intravenous injection of
an emulsion of 7-12-dimethylbenzanthra-
cene at a dose level of 4 mg per kg body
weight. Itwas seriallytransplanted using
a trocar, and tumours from the 5th and
6th transplants were used in the present
experiments. On days 6, 12 and 16
the treated rats received an intraperi-
toneal, and 2 intramuscular injections of
0 5 ml Freund's complete adjuvant (Difco
Laboratories). A pilot experiment had
demonstrated that administration of the
adjuvant on the first or second day
after transplantation completely inhibited
tumour growth. The later administra-
tion of adjuvant produced an arrest in
tumour growth (Fig. 1), which lasted
from the 12th to the 18th day after
implantation, after which growth was
rapidly resumed. 3H-thymidine was
given on day 13.
METHODS
Measurements of mean tumour diameter
were made every 1 or 2 days and tumour
weights were calculated assuming them to
be unit density spheres. The growth curves
were plotted as the mean weight of 15-25 rat
tumours and 12-15 mouse tunmours. The
rats received 150 ,Ci and the mice 50 uCi
of 3H-thymidine (Radiochemical Centre,
Amersham, specific activity greater than
10 Ci/mM) by intraperitoneal injection. For
the continuous labelling of the rat tumours,
75 ,uCi of thymidine was injected intra-
peritoneally every 8 hours for a period of
3-5 days. The tumours were fixed in
formalin and paraffin sections were cut at
5 ,tm. The slides were dipped in Ilford K5
liquid emulsion, exposed for 3-4 weeks and
stained with haematoxylin and eosin after
photographic processing. Labelling index
was determined on 2000 interphase cells
and for each point on the labelled mitoses
curves about 100 mitoses were scored in
one tumour. The grain count criterion was
5 grains or more.
RESULTS
The results of investigations by the
technique of labelled mitoses (Quastler
and Sherman, 1959; Mendelsohn, 1960)
are shown in Fig. 2-4. In each case
the full lines show the best fitting curves
calculated by the method of Steel and
Hanes (1971) and the corresponding
median phase durations are listed in
Table I. The reasoning behind this
method of analysis is to try to simulate
the data using a theoretical model of the
cell cycle in which the phases G1, S and
G2 are defined by independent lognormal
distributions. If the data can be satis-
factorily simulated then it is possible to
deduce reliable estimates of the mean
(and less reliably of the variance) of the
phase durations. If the data cannot in
part be simulated, then the analysis
indicates that the theoretical model is
in some respect inadequate (see Steel,
1970, 1972, for a discussion of the possible
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FIG. 2.-Labelled mitoses curves for the
control and treated L5178 lymphoma.
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Fio. 3. Labelle(d mitoses curves for the control and treated BICR/A3 osteosarcoma.
souirces of discrepancy between the data
and theoretical curves). Usually this
will mean that it is not possible without
further information about the tumour
to draw reliable inferences concerning the
transit time of cells through one or
more phases of the cell cycle.
For the L,51 78Y lymphoma the 2
labelled mitoses curves are very similar,
despite the fact that the control tumours
had a voluime doubling time of 18 hours
and the tumours in immunized mice
were not growing. Within the precision
of the data the theoretical curves are
probably a satisfactory fit.
The 3 labelled mitoses curves on the
BICR/A3 osteosarcoma are also very
similar. For this tumour, however, there
are more experimental points beyond the
first day after thymidine injection and
in the 2 treated groups these points all
lie below the theoretical curves. This
type of discrepancy has been found in
other experimental labelled mitoses data
on tumours and is an example of what
has been termed " fade " (Steel, 1972).
There are 2 possible implications:
(i) A preferential loss of labelled cells
either by an autoradiographic
artefact (e.g. cells reducing their
grain count below the counting
threshold) or by a biological
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process that has been ignored in
the theoretical calculations (e.g.
radiation effect from the tritium
label).
(ii) A heterogeneous cell population,
all cells having similar G2 and S
distributions but with a sub-
population of cells that have a
very long G1 period (no second
peak within the period of obser-
vation).
It has not been possible to identify
the cause offade inthisparticularinstance,
but bearing in mind that one of the
treated groups of tumours was growing
faster, and one slower, than the controls
which did not show fade, these discre-
pancies do not prevent the conclusion
that the two treatments had little effect
on the timing of the mitotic cycle in
the tumour cells. The continuous label-
ling data for the rat osteosarcoma are
shown in Fig. 5. The theoretical curves
have been computed on the basis of a
model in which proliferating cells have
cell cycle parameters corresponding to
the computed labelled mitoses curves and
in which non-proliferating cells are pro-
duced at mitosis with a fixed probability.
Three forms of the model have been
used (Steel, Adams and Barrett, 1966;
Steel and Hanes, 1971) in which cell loss
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FIG. 4.-Labelled mitoses curves for the
control and treated BICR/A12 adeno-
carcinoma.
is considered to occur from the oldest
non-proliferating cells (SAB1), from cells
shortly after mitosis (SAB2) or randomly
from the whole population (SAB3). All
of the corresponding theoretical curves
lie well above the experimental data.
The loss of cells near mitosis seems the
most plausible assumption (Fig. 5) but
it is clear that other factors are involved.
It could be that a more elaborate model
TABLE I.-Summary ofCell Kinetic Results
L5178Y Lymphoma
Control
Immunized
BICR/A3 Osteosarcoma
Control
Immunized
Irradiated
BICR/A12 Adenocarcinoma
Control
Immunized
Volume
doubling
time
(hours)
Labelling
index
(%) G1 S G2 Ti GF KP
18 . 48 . 2-7 . 6-5 . 1 1 . 10 . 90 . 0-058 . 40
00 . 38 . 2-5 . 6-8 . 2-0 . 11 68 . 0 045 . 100
60
62
48
27
20
30
. 5.2 . 8.7 . 2-4 . 16 . 56 0.027 62
. 6-0 . 7-8 . 2-8 . 16 . 55 . 0-022 . 57
. 4-2 . 8*5 . 1-8 . 14 58 0-030 . 57
90 . 28 . 9-4 . 8-9 . 2-4 . 21 . 87 . 0-027 72
00 . 31 . 6*4 . 14 9 . 2-7 . 23 . 67 0.017 . 100
Key: Ti: estimated median intermitotic time in hours.
G1, S, G2: estimated median phase durations in hours.
GF: growth fraction (%).
Kp: rate constant for cell production (per hour).
cp: cell loss factor (the rate of cell loss as a percentage of the rate of cell production).
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FIG;. 5. The percentage of labelled cells
in the osteosarcoma BICR/A3 during
repeated labelling with 3H-thymidine. The
full lines show theoretical calculations
(see text).
with a sub-population of slowly pro-
liferating cells might satisfy both the
labelled mitoses and continuous labelling
data for this tumour.
For the BICR/A12 adenocarcinoma
an effect of treatment on the labelled
mitoses curve is observed. The first
peak is much broader in the treated
than the control tumours and beyond
the first 24 hours after thvmidine injection
the points for treated tumours are at
each time interval higher than in control
tumours. The data thus imply an in-
crease in the duration of the S period.
Simulation by the theoretical curves is
good in the region of the first peak. The
data beyond the first peak are not well
fitted for either group of tumours mainly
because of the immediate damping which
they exhibit and because of the low
points at 42 hours. The parameters
given in Table I for G1 and the whole
mitotic cycle are therefore only approxi-
mately correct.
For each type of tumour, calculations
have been made of growth fraction
(Mendelsohn, 1960) and cell loss factor
(Steel, 1968). These were made using
the computer program described by
Steel and Hanes (1971). The growth
fraction is found by comparing the
labelling index of the whole population
after one injection of thymidine with a
theoretical labelling index of proliferating
cells, calculated from the parameters of
the cell cycle. The cell loss factor is
found by comparing the actual volume
9
doubling time with the doubling time of
the cell population that would be expected
from the observed labelling index if all
cells were conserved. The use of a
volume doubling time rather than a cell
population doubling time for these cal-
culations assumes that the mean number
of cells per unit volume was not changing
rapidly with time. The results of these
calculations are given in Table I.
DISCUSSION
The 3 tumours used in this study
were a varied group, differing in histo-
logical type, species of host, number of
transplantation passages and responsive-
ness to a disturbance of the immuno-
logical status of the host. To this group
may be added the Ehrlich ascites tumour
during rejection after transplantation into
rats, which has been described previously
(Janik, 1971). The main conclusion which
can be drawn is that even if tumour
growth is completely arrested by an
immunological response of the host, there
is little change in the timing of the
mitotic cycle in those cells that continue
to proliferate. This is clearly the situa-
tion in the L5178Y lymphoma where the
labelled mitoses curves are probably
statistically indistinguishable despite the
fact that the control tumours had a
volume doubling time of 18 hours and
the treated tumours were not growing.
For the BICR/A3 osteosarcoma the
labelled mitoses curves are also very
similar. This, however, is a less con-
vincing result because the 2 treatments
produced only a moderate change in
tumour growth rate. For the BICR/A12
adenocarcinoma the change in the dura-
tion of the DNA synthetic period is
significant but the analysis of the data
suggests that there was no great increase
in the duration of the cell cycle as a
whole. This case therefore also supports
the conclusion that an immunologically
induced arrest of tumour growth was not
associated with a marked slowing of the
mitotic cycle in those cells that con-
tinued to proliferate.
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What is observed is that in each case
where there was a slowing of growth rate
there was a reduction in cell production
rate. In the case of the adenocarcinoma
the rate of cell loss even before treatment
was 72% of the rate of cell production,
and the decrease in cell production rate
is by itself sufficient to explain the arrest
of growth. In the case of the lymphoma
the arrest of growth must in part have
been due to an absolute increase in the
rate of cell loss. The estimates of the
growth fraction decrease, but it would be
false to draw any precise conclusions
from this. In all of these tumours
there was a broad distribution of inter-
mitotic times, indicated by the rapid
damping of the labelled mitoses curves.
The data give little information on the
form of these distributions and the
discrepancies seen between the data and
theoretical curves for the osteosarcoma
and adenocarcinoma at later intervals,
suggest that the true distributions of
intermitotic time may differ considerably
from those assumed in the theoretical
calculations. As pointed out by Steel
(1972), calculations of the growth fraction
(the proportion of proliferating cells) are
invariably based on an implied definition
of " proliferating cells " as " those cells
whose characteristics are represented by
the labelled mitoses curve ". It is clear
that in the present results, as in many
others, there is little information on
proportion of cells with long intermitotic
time. The significance of the lowering
of the growth fraction is thus that there
has been a reduction in the proportion
of cells that have a short or average inter-
mitotic time, with a consequent increase
in the proportion that are either non-
proliferating or proliferating very slowly.
If the immune reaction operates through
a direct cytotoxic process which affects
only a proportion of the cells in the
tumour, and if the cells that are being
attacked take time to disappear, then
this by itself would produce a reduction
in the estimates of growth fraction.
We acknowledge with gratitude the
support and encouragement of Professor
L. F. Lamerton, also the expert technical
assistance of Miss K. Adams and Mrs
J. Lucas.
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